Breast biopsies after neoadjuvant chemotherapy accurately predict presence of residual breast cancerUniversity of Texas M. D. Anderson Cancer CenterResearchers from The University of Texas MD Anderson Cancer Center have identified a standardized protocol that uses image-guided breast biopsies to reliably predict residual disease in breast cancer patients and that potentially identifies exceptional responders who may not require surgery. Channels: Cancer, Cell Biology, Women's Health, Cancer Center Featured Story 2, Embargoed Feed - hidden, Medical Meetings, Keywords: Md Anderson, MD Anderson Cancer Center, San Antonio Breast Cancer Symposium, San Antonio Breast Symposium, Breast Cancer Released:10-Dec-2019 5:05 PM EST |
![]()
The Rapid Tissue Donation Program at Moffitt Cancer Center Offers a Feasible Approach to Improve ResearchMoffitt Cancer CenterIn an article published in Cancer Medicine, Moffitt Cancer Center scientists describe a community-based program called the Rapid Tissue Donation (RTD) protocol. It enables patients to consent to donating tumor tissue and blood samples for research purposes after their death. The samples provided by patients postmortem enable researchers to study the genetic and molecular makeup of primary and metastatic tumors after the patient failed treatment, and to compare those finding with what was known about the patient during earlier phases of their therapy. Channels: Cancer, Ethics and Research Methods, Healthcare, Cancer Center Featured Story 2, All Journal News, Keywords: Rapid Tissue Donation, tumor tissue, Postmortem, Moffitt Cancer Center Released:13-Dec-2019 10:00 AM EST |
Residual cancer burden after neoadjuvant therapy can accurately predict breast cancer survivalUniversity of Texas M. D. Anderson Cancer CenterResearchers from The University of Texas MD Anderson Cancer Center today reported results from a pooled analysis of more than 5,100 breast cancer patients that found residual cancer burden (RCB) continuous index and classification were independently and strongly prognostic for all breast cancer phenotypes. Channels: Cancer, Cell Biology, Women's Health, Cancer Center Featured Story 2, Embargoed Feed - hidden, Medical Meetings, Keywords: MD Anderson Cancer Center, San Antonio Breast Cancer Symposium, San Antonio Breast Symposium, Breast Cancer, Md Anderson Released:10-Dec-2019 5:05 PM EST |
Analysis of Different Treatment Strategies for Non-Invasive Breast Cancer Shows Radiation Treatment Alone is Cost-EffectiveRutgers Cancer Institute of New JerseyRutgers Cancer Institute of New Jersey investigators evaluated all treatment strategies for both standard-risk and good-risk ductal carcinoma in-situ and found the most commonly recommended combination treatment for DCIS represents low-value care, while radiation therapy alone was cost-effective. Channels: All Journal News, Cancer, Healthcare, Women's Health, Local - New Jersey, Cancer Center Featured Story 2, Medical Meetings, Keywords: Ductal Carcinoma In Situ, Dcis, Breast Cancer, Early Stage Breast Cancer, Radiation Treatment, Sabcs, San Antonio Breast Cancer Symposium, Rutgers University, New Jersey Released:11-Dec-2019 2:05 PM EST |
![]()
Closing Gaps in Perspective of Value between Cancer Patients and their Health Care ProvidersNational Comprehensive Cancer Network® (NCCN®)NCCN hosted an annual NCCN Patient Advocacy Summit: Delivering Value for Patients across the Oncology Ecosystem in Washington, DC, bringing together patients, advocates, clinicians, policy-makers, and others to share diverse perspectives on the meaning of value in cancer care. Channels: Women's Health, Cancer Center Featured Story 2, Keywords: NCCN, National Comprehensive Cancer Network, NCCNPolicy, NCCN Patient Advocacy Summit, Cancer Patients, Cancer Advocacy, Patient Advocate, patient advocacy, patient reported outcomes, shared decision-making , cancer survivor advocacy, Fertility Preservation, Sexual Health, financial toxicity of cancer Released:11-Dec-2019 2:00 PM EST |
Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patientsUniversity of Texas M. D. Anderson Cancer CenterResearchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial. Channels: Cancer, Cell Biology, Pharmaceuticals, Women's Health, Cancer Center Featured Story 2, Embargoed Feed - hidden, Medical Meetings, Keywords: Md Anderson, San Antonio Breast Symposium, San Antonio Breast Cancer Symposium, Breast Cancer Released:10-Dec-2019 5:05 PM EST |
A New Era of Care: The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center to Open in January 2020Memorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer Center (MSK) today celebrated the opening of a $1.5 billion state-of-the-art cancer treatment facility with government officials, members of the Boards of Overseers and Managers, and staff. Opening for patient care next month, the 750,000-square-foot building is the institution’s — and the city’s — largest freestanding cancer care facility. The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center is a healing community dedicated to patient-centered care, made possible by a landmark donation and a pioneering vision that signifies a new era of cancer care. Channels: All Journal News, Cancer, Healthcare, In the Workplace, Cancer Center Featured Story 2, Keywords: Memorial Sloan Kettering Cancer Center, David H. Koch, Cancer Care, outpatient care Released:10-Dec-2019 3:55 PM EST |
Yale Cancer Center researchers investigate inducing “synthetic lethality” in two blood and bone cancersYale Cancer CenterIn a clinical trial led by Yale Cancer Center (YCC) and Smilow Cancer Hospital, researchers aim to exploit DNA mutations in the treatment of two blood and bone marrow cancers, a different tacit than the more traditional approach of blunting or switching off genetic mutations linked to cancer Channels: All Journal News, Blood, Cancer, Genetics, Healthcare, Cancer Center Featured Story 2, Medical Meetings, Keywords: Yale Cancer Center, Cancer, Smilow Cancer Hospital, Oncology, Blood Cancers, Dr. Thomas Prebet, Namrata Chandhoka, M.D., Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia Released:10-Dec-2019 10:55 AM EST |
![]()
NCCN Announces Projects Funded for Metastatic Breast Cancer Grant Program, in Collaboration with PfizerNational Comprehensive Cancer Network® (NCCN®)The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces proposals selected for funding, in collaboration with Pfizer Global Medical Grants, to improve the quality of care and outcomes for people with metastatic breast cancer (MBC). Channels: All Journal News, Cancer, Healthcare, Women's Health, Grant Funded News, Cancer Center Featured Story 2, Keywords: NCCN, National Comprehensive Cancer Network, nccn oncology research program, NCCN orp, Metastatic Breast Cancer, mBC, Breast Cancer Released:10-Dec-2019 8:35 AM EST |
Combination therapy results in 98% response rate for some newly diagnosed leukemia patientsUniversity of Texas M. D. Anderson Cancer CenterA study combining low-dose chemotherapy with a monoclonal antibody is effective for older patients with Philadelphia chromosome-negative ALL. Channels: Pharmaceuticals, Seniors, Cancer Center Featured Story 2, Embargoed Feed - hidden, Medical Meetings, Keywords: ALL acute lymphoblastic leukemia, Acute Lymphoblastic Leukemia, Nicholas D.P Cosford, Philadelphia chromosome-like acute lymphoblastic leukemia Released:4-Dec-2019 11:50 AM EST |